Chronic obstructive pulmonary disease. Current concepts and therapeutic approaches.

IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Chest Pub Date : 1990-02-01 DOI:10.1378/chest.97.2.19s
N J Gross
{"title":"Chronic obstructive pulmonary disease. Current concepts and therapeutic approaches.","authors":"N J Gross","doi":"10.1378/chest.97.2.19s","DOIUrl":null,"url":null,"abstract":"<p><p>The fifth leading cause of death in the United States, chronic obstructive respiratory conditions, cannot be cured but can be considerably ameliorated by appropriate management. Many patients with COPD have a combination of chronic bronchitis, asthma, and emphysema. While the damage due to emphysema is permanent, many of the pathophysiologic changes of asthma and bronchitis can be reversed to some extent, and such reversal should be a goal of therapy. Smoking cessation will help the patient more than any other medical treatment. Bronchodilator therapy is best given by inhalation from a metered dose inhaler and on a maintenance basis. Be sure to check inhaler technique. An anticholinergic agent, eg, ipratropium bromide, is probably most effective, but many patients prefer a beta 2-selective adrenergic agent. Xanthines are currently third choice but are very useful to cover nocturnal dyspnea. Corticosteroids are usually only used in acute exacerbations and then only for short courses. If prolonged use is required, however, the inhalation route minimizes side effects to which these patients are particularly prone. Antibiotics are also usually only used in exacerbations, but one can be liberal with them. Use the less expensive broad-spectrum options for ten days. Some clinicians believe that hydration is an effective expectorant. Mucolytic therapy is extensively used outside the United States. The appropriate role of mucolytic therapy in the treatment of bronchitis remains to be more fully explored. Low-flow oxygen is only used in the prevention or treatment of cor pulmonale when the PaO2 is persistently at or below 55, or with a rising hematocrit and right-sided cardiac changes. If used, oxygen is helpful only when given long term for at least 18 h per day, not on a prn basis. Cardiac glycosides are probably of little benefit, but diuretics have an important role in treatment of fluid retention. Pulmonary vasodilator therapy is still experimental, as is almitrine. Prophylaxis with pneumococcal vaccine and annual influenza vaccine is rational but has not been proven to be of value. Exercise and activity should be encouraged for all except those with frank congestive heart failure. The role of \"breathing exercises\" is currently being reevaluated. Surgery has almost no place in the management of COPD. Anesthesia often results in postoperative complications in this disease. Avoid all sedatives and tranquilizers.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":"97 2 Suppl","pages":"19S-23S"},"PeriodicalIF":9.5000,"publicationDate":"1990-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1378/chest.97.2.19s","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1378/chest.97.2.19s","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 29

Abstract

The fifth leading cause of death in the United States, chronic obstructive respiratory conditions, cannot be cured but can be considerably ameliorated by appropriate management. Many patients with COPD have a combination of chronic bronchitis, asthma, and emphysema. While the damage due to emphysema is permanent, many of the pathophysiologic changes of asthma and bronchitis can be reversed to some extent, and such reversal should be a goal of therapy. Smoking cessation will help the patient more than any other medical treatment. Bronchodilator therapy is best given by inhalation from a metered dose inhaler and on a maintenance basis. Be sure to check inhaler technique. An anticholinergic agent, eg, ipratropium bromide, is probably most effective, but many patients prefer a beta 2-selective adrenergic agent. Xanthines are currently third choice but are very useful to cover nocturnal dyspnea. Corticosteroids are usually only used in acute exacerbations and then only for short courses. If prolonged use is required, however, the inhalation route minimizes side effects to which these patients are particularly prone. Antibiotics are also usually only used in exacerbations, but one can be liberal with them. Use the less expensive broad-spectrum options for ten days. Some clinicians believe that hydration is an effective expectorant. Mucolytic therapy is extensively used outside the United States. The appropriate role of mucolytic therapy in the treatment of bronchitis remains to be more fully explored. Low-flow oxygen is only used in the prevention or treatment of cor pulmonale when the PaO2 is persistently at or below 55, or with a rising hematocrit and right-sided cardiac changes. If used, oxygen is helpful only when given long term for at least 18 h per day, not on a prn basis. Cardiac glycosides are probably of little benefit, but diuretics have an important role in treatment of fluid retention. Pulmonary vasodilator therapy is still experimental, as is almitrine. Prophylaxis with pneumococcal vaccine and annual influenza vaccine is rational but has not been proven to be of value. Exercise and activity should be encouraged for all except those with frank congestive heart failure. The role of "breathing exercises" is currently being reevaluated. Surgery has almost no place in the management of COPD. Anesthesia often results in postoperative complications in this disease. Avoid all sedatives and tranquilizers.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性阻塞性肺病。当前的概念和治疗方法。
慢性阻塞性呼吸系统疾病是美国第五大死亡原因,无法治愈,但通过适当的管理可以大大改善。许多慢性阻塞性肺病患者同时患有慢性支气管炎、哮喘和肺气肿。虽然肺气肿造成的损害是永久性的,但哮喘和支气管炎的许多病理生理变化在一定程度上是可以逆转的,这种逆转应该是治疗的目标。戒烟对病人的帮助比任何其他药物治疗都要大。支气管扩张剂治疗最好是通过计量吸入器吸入并在维持基础上给予。一定要检查吸入器技术。抗胆碱能药物,如异丙托溴铵,可能是最有效的,但许多患者更喜欢β 2选择性肾上腺素能药物。黄嘌呤目前是第三种选择,但对治疗夜间呼吸困难非常有用。皮质类固醇通常只用于急性加重,而且只用于短期治疗。然而,如果需要长期使用,则吸入途径可将这些患者特别容易发生的副作用降至最低。抗生素通常也只在病情加重时使用,但可以随意使用。使用更便宜的广谱选择10天。一些临床医生认为水合作用是有效的祛痰剂。黏液溶解疗法在美国以外广泛使用。粘液溶解疗法在支气管炎治疗中的适当作用仍有待更充分的探讨。低流量氧仅用于预防或治疗肺心病时,PaO2持续在55或以下,或有上升的血细胞比容和右侧心脏改变。如果使用,氧气是有帮助的,只有长期给予至少18小时,每天,而不是在基本的基础上。心糖苷可能没有什么益处,但利尿剂在治疗液体潴留方面有重要作用。肺血管扩张剂治疗仍处于实验阶段,almitine也是如此。预防肺炎球菌疫苗和每年流感疫苗是合理的,但尚未被证明是有价值的。除了那些有明显充血性心力衰竭的人外,应该鼓励所有人进行锻炼和活动。“呼吸练习”的作用目前正在被重新评估。手术在慢性阻塞性肺病的治疗中几乎没有地位。麻醉常常导致这种疾病的术后并发症。避免使用任何镇静剂和镇静剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
期刊最新文献
Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Characteristic Pulmonary Impedance With Exercise Detects Abnormal Pulmonary Vascular Response and Uncoupling in Pulmonary Hypertension Resulting From Heart Failure With Preserved Ejection Fraction. Deciphering the role of FDG-PET/CT in the management of sarcoidosis. Diagnostic Yield and Synergistic Impact of Needle Aspiration and Forceps Biopsy with Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions (CONFIDENT-ENB): A Randomized Controlled Trial. Estimating the Causal Effect of Double-Blind Peer Review for a Pulmonary, Critical Care, and Sleep Medicine Journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1